相关实验视频

Updated: May 23, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

拉泽提尼布:一种针对非小细胞肺癌的新型EGFR-TKI疗法

Dhairavi Shah¹, Dhaara Shah¹, Suzy Ndandji¹

¹Chemometrics and Molecular Modeling Laboratory, Department of Chemistry and Physics, Kean University, Union, NJ, USA.

Expert opinion on drug metabolism & toxicology

|May 15, 2025

概括

拉泽提尼布是一种第三代EGFR TKI,对非小细胞肺癌 (NSCLC) 患者,特别是那些脑转移或对先前疗法的耐药性患者有前途. 需要进一步的研究来克服新出现的抗药机制.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

非小细胞肺癌 (NSCLC) 是最常见的肺癌类型.
先进的NSCLC和对表皮生长因子受体氨酸激酶抑制剂 (EGFR TKI) 的耐药性存在重大治疗挑战.
拉泽提尼布是一种第三代EGFRTKI,向EGFR突变,包括T790M.

研究的目的:

审查拉泽提尼布的开发,作用机制,临床疗效和安全性.
评估拉泽提尼布在治疗晚期NSCLC中的潜力,特别是在抗药性和大脑转移的情况下.

主要方法:

对比拉泽提尼布与奥西默提尼布的临床前研究的综述.
对拉泽提尼布单一疗法和与阿米万他马布联合治疗的临床试验数据的分析.
检查新出现的抗性突变和未来的治疗策略.

主要成果:

临床前数据表明,相比于奥西默提尼布,拉泽提尼布对突变EGFR具有优越的选择性,并增强了血脑屏障的透能力.
临床试验表明,在先进的NSCLC中,拉泽提尼布的无进展生存率和响应持续时间有所改善.
拉泽提尼布作为单一疗法和与阿米万塔马布结合的疗法都显示出有效性.

结论:

拉泽提尼布是EGFR突变NSCLC的一种有前途的治疗方法,特别是在脑转移或对先前EGFRTKI耐药性的患者中.
像C797S这样的新兴耐药突变需要对新型疗法进行持续研究,包括组合治疗和第四代TKI.
持续创新对于优化NSCLC治疗结果至关重要.

关键词:

欧洲农业基金会 (EGFR) 是一个基金.在NSCLCLC中,我们可以看到NSCLCLC.T790M二次突变的二次突变这里是TKI TKI.拉泽蒂尼布 (Lazertinib) 是一种治疗方法.

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...